Kumar Amit, CEO of Anixa Biosciences, Inc. (NASDAQ:ANIX), purchased 10,000 shares, increasing his total ownership to 569,925 shares.
Anixa’s innovative breast cancer vaccine targets ?-lactalbumin in malignant cells, aiming to revolutionize cancer prevention and treatment.
Despite financial challenges, ANIX’s low debt-to-equity ratio and strong current ratio suggest a stable foundation for its projects.

On June 4, 2025, Kumar Amit, CEO of Anixa Biosciences, Inc. (NASDAQ:ANIX), made a significant investment in his company by purchasing 10,000 shares of the company’s common stock at $2.85 each. This strategic acquisition increased his total ownership to 569,925 shares, demonstrating a strong belief in the company’s future prospects. Anixa, a pioneering biotechnology firm, is at the forefront of developing a breast cancer vaccine, a groundbreaking approach to cancer treatment.

Anixa’s breast cancer vaccine is a significant development in the field of cancer treatment. The vaccine specifically targets the protein ?-lactalbumin, found in malignant cells during breast cancer, activating the immune system to attack these cells. This innovative method was highlighted by Dr. Amit Kumar on NewsNation’s “Elizabeth Vargas Reports.” The company has completed enrollment for its Phase 1 clinical trial of the vaccine, developed in collaboration with the Cleveland Clinic. This trial, funded by the U.S. Department of Defense, is a critical step in demonstrating the vaccine’s effectiveness.

Despite its promising research, ANIX faces financial challenges, with a negative P/E ratio of -7.31 and an enterprise value to operating cash flow ratio of -11.41. The earnings yield is also negative at -13.68%, indicating current financial struggles. However, ANIX has a low debt-to-equity ratio of 0.0129 and a strong current ratio of 9.35, suggesting a solid ability to cover short-term liabilities. These financial metrics indicate that while ANIX faces challenges, it has a stable financial foundation to support its innovative projects.